CA-SCIENTIST.COM
1.4.2021 13:57:06 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading marketplace for life science research, announced today that it has partnered with Charles River , Certis Oncology and other leading oncology CROs to launch a Disease Model Finder that helps medical researchers use genetic, cellular and patient data to find the most appropriate research models for their preclinical development projects.
“Our proprietary model selection software uses multiple machine learning algorithms to help researchers sift through large amounts of data and identify in vitro and in vivo models for their research,” stated Javier Pineda, PhD, Data Scientist at Scientist.com. “Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.”
The Disease Model Finder brings together a wealth of data that can help scientists choose the right preclinical disease models. DNA sequencing data from CRO partners is uploaded and analyzed so that researchers can easily search for models based on the presence (or absence) of a mutated gene or by the up or down regulation of gene expression. Marketplace customers can then filter their search results based on cancer type, subtype and characteristics or patient information.
“Scientist.com’s new Disease Model Finder will enable pharma and biotech researchers to find and purchase the most appropriate Charles River models for their drug development programs,” said Melissa Schroeder, E-Commerce Manager at Charles River. “Having access to advanced data that better matches a patient-derived xenograft (PDX) model with a research program will enable optimal study design, ultimately saving time and money as clients race to get critical therapies to patients.”
At launch, the Disease Model Finder includes 650 PDX models provided by Charles River, Certis, XenTech , the Lab for Innovated Diagnosis and Experimental Therapeutics (LIDE) and others—a number that is projected to grow quickly as more CROs join the program. By 2022, the platform will include other model systems including organoids, cell-derived xenografts (CDX), syngeneic models, immunoncology models and patient-derived cell lines.
“With so many drugs failing in human clinical trials because they don’t work, it is imperative that we use more predictive preclinical models of disease,” stated Peter Ellman, Certis Oncology CEO. “By combining gene analysis, patient data and tissue profiling data, Scientist.com’s Disease Model Finder increases the odds that researchers are selecting the right Certis models for translational drug development.”
To learn more please visit https://www.scientist.com/disease-model-finder/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Actus Nutrition Achieves Certified B Corporation™ Status13.7.2026 17:51:00 CEST | Press release
Certification reinforces Actus Nutrition’s commitment to responsible manufacturing, strong communities, and long-term stakeholder value. Actus Nutrition today announced that it has achieved Certified B Corporation™ status, joining a global community of businesses that value social and environmental performance, accountability, and transparency. For more than 80 years, Actus Nutrition has upcycled dairy-based raw materials into high-value nutrition ingredients used by customers around the world. Earning B Corp certification reflects the company’s belief that business success should create value not only for stakeholders, but also for employees, customers, suppliers, communities, and the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713867540/en/ Actus Nutrition achieves Certified B Corporation status. "We've always believed that how a company operates matters just as much as what it produces," said David Lenz
AIT Worldwide Logistics Welcomes Justin Kosslyn as Chief Digital and Technology Officer13.7.2026 17:02:00 CEST | Press release
Proven leader with Google experience to advance company’s AI-powered digital transformation Supply chain solutions leader AIT Worldwide Logistics has hired Justin Kosslyn, a tenured software development executive, as its chief digital and technology officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713269550/en/ Justin Kosslyn will lead an accelerating digital transformation at AIT Worldwide Logistics, unifying a vastly diverse array of shippers and partners across the globe. In the newly created role, Kosslyn will report directly to President and Chief Operating Officer, Keith Tholan, and lead the company’s global technology strategy, continuing to implement AIT’s existing program while accelerating the next generation of integrated digital, data, AI and customer-facing systems across the organization. “With a history of delivering for companies at the center of global technology and innovation, Justin brings the k
Labaton Keller Sucharow LLP Launches Corporate Accountability & Governance Task Force13.7.2026 16:46:00 CEST | Press release
Labaton Keller Sucharow LLP is pleased to announce the launch of its new Corporate Accountability & Governance Task Force, designed to help institutional investors advance corporate accountability while pursuing meaningful shareholder recoveries. Created in response to the increasing needs of our clients, the Task Force will provide clients with strategic advice on opportunities to drive positive corporate change through securities and shareholder litigation. This initiative reflects the Firm’s longstanding commitment to protecting investor interests while promoting responsible corporate conduct. Labaton partners with institutional investor clients to pursue cases that not only seek financial recovery but also encourage meaningful corporate reforms and reinforce sound governance practices. The Task Force is chaired by Partners Carol C. Villegas and Domenico “Nico” Minerva, who have led some of the Firm's most significant matters involving corporate accountability and governance reform.
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom